| 2026年中报 | 2025年年报 | 2025年中报 | 2024年年报 | 2024年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| 生物制品(原料药及制剂产品)(元) | 2,046,928,639.74 | 3,801,634,792.58 | 1,964,412,393.25 | 2,693,527,810.55 | 1,223,532,404.36 |
| 特许经营权前期服务(元) | - | - | 2,936,503.84 | 135,337,835.49 | 1,395,594.84 |
| 化药(元) | - | - | 2,474,153.79 | 2,888,247.61 | - |
| 国际-特许权服务收入(元) | 93,835,357.39 | 4,753,470.57 | - | - | - |
| 其他(元) | 82,257,843.34 | 233,605,064.53 | 96,972,591.89 | 213,593,911.46 | 89,964,846.05 |
| 营业成本(元) | |||||
| 生物制品(原料药及制剂产品)(元) | 519,582,849.17 | 817,891,679.21 | 424,340,810.61 | 631,843,281.14 | 294,534,129.15 |
| 特许经营权前期服务(元) | - | - | 244,778.07 | 6,658,618.31 | - |
| 化药(元) | - | - | 2,586,066.90 | 2,809,440.44 | - |
| 国际-特许权服务收入(元) | 122,670.65 | 522,824.46 | - | - | - |
| 其他(元) | 55,487,768.81 | 158,277,173.57 | 63,705,359.04 | 125,194,928.98 | 54,564,641.85 |
| 毛利(元) | |||||
| 生物制品(原料药及制剂产品)(元) | 1,527,345,790.57 | 2,983,743,113.37 | 1,540,071,582.64 | 2,061,684,529.41 | 928,998,275.21 |
| 特许经营权前期服务(元) | - | - | 2,691,725.77 | 128,679,217.18 | 1,395,594.84 |
| 化药(元) | - | - | -111,913.11 | 78,807.17 | - |
| 国际-特许权服务收入(元) | 93,712,686.74 | 4,230,646.11 | - | - | - |
| 其他(元) | 26,770,074.53 | 75,327,890.96 | 33,267,232.85 | 88,398,982.48 | 35,400,204.20 |
| 毛利率(%) | |||||
| 生物制品(原料药及制剂产品)(%) | 74.62 | 78.49 | 78.40 | 76.54 | 75.93 |
| 特许经营权前期服务(%) | - | - | 91.66 | 95.08 | - |
| 化药(%) | - | - | -4.52 | 2.73 | - |
| 国际-特许权服务收入(%) | 99.87 | 89.00 | - | - | - |
| 其他(%) | 32.54 | 32.25 | 34.31 | 41.39 | 39.35 |
| 收入构成(%) | |||||
| 生物制品(原料药及制剂产品)(%) | 92.08 | 94.10 | 95.05 | 88.45 | 93.05 |
| 特许经营权前期服务(%) | - | - | 0.14 | 4.44 | 0.11 |
| 化药(%) | - | - | 0.12 | 0.09 | - |
| 国际-特许权服务收入(%) | 4.22 | 0.12 | - | - | - |
| 其他(%) | 3.70 | 5.78 | 4.69 | 7.01 | 6.84 |
| 毛利构成(%) | |||||
| 生物制品(原料药及制剂产品)(%) | 92.69 | 97.40 | 97.73 | 90.47 | 96.19 |
| 特许经营权前期服务(%) | - | - | 0.17 | 5.65 | 0.14 |
| 化药(%) | - | - | -0.01 | 0.00 | - |
| 国际-特许权服务收入(%) | 5.69 | 0.14 | - | - | - |
| 其他(%) | 1.62 | 2.46 | 2.11 | 3.88 | 3.67 |